Progressive hypertrophy regression with sustained pressure reduction in hypertension: The Losartan Intervention for Endpoint Reduction study

Journal of Hypertension

Volumn 20, Issue 7, 2002, Pages 1445-1450

  Devereux, Richard B ^a   Palmieri, Vittorio ^a   Liu, Jennifer E ^a   Wachtell, Kristian ^a   Bella, Jonathan N ^a   Boman, Kurt ^a   Gerdts, Eva ^a   Nieminen, Markku S ^a   Papademetriou, Vasilios ^a   Dahlöf, Björn ^a  

^a Division of Cardiology   (United States)

Author keywords

Echocardiography; Hypertension; Hypertrophy; Regression

Indexed keywords

ATENOLOL; LOSARTAN; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ECHOCARDIOGRAPHY; FEMALE; GEOMETRY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE WALL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; THICKNESS; TREATMENT OUTCOME; BIOASSAY; BLOOD PRESSURE; COMPARATIVE STUDY; DISEASE COURSE; ECHOGRAPHY; EUROPE; FOLLOW UP; HEART VENTRICLE; HEART VENTRICLE REMODELING; HEMODYNAMICS; HYPERTENSION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREVALENCE; REGRESSION ANALYSIS; TIME; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; ENDPOINT DETERMINATION; EUROPE; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; PREVALENCE; REGRESSION ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VENTRICULAR REMODELING;

EID: 0036628769     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200207000-00033     Document Type: Article

References (39)

1. The role of preclinical cardiovascular disease in the evolution from risk factor exposure to the development of clinical morbid events
2. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension
3. Prognostic implications of echocardiographically-determined left ventricular mass in the Framingham Heart Study
4. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults
5. Prognostic significance of left ventricular hypertrophy
6. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Multicenter trial
7. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment
8. Prognostic significance of serial changes in left ventricular mass in essential hypertension
9. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy
10. Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials
11. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies
12. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996)
13. Treatment of Mild Hypertension Study: Final results
14. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS)
15. The Losartan Intervention for Endpoint reduction (LIFE) Study in Hypertension. Rationale, design and methods
16. The Losartan Intervention for Endpoint (LIFE) Reduction in Hypertension Study - Baseline characteristics of 9,194 patients with left ventricular hypertrophy
17. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The LIFE Study
18. Comparison of enalapril vs nifedipine to decrease left ventricular hypertrophy in systemic hypertension (The PRESERVE Trial)
19. Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: The Strong Heart Study
20. Evaluation of cardiac and vascular structure by echocardiography and other noninvasive techniques
21. The Committee on M-mode Standardization of the American Society of Echocardiography: Recommendations regarding quantitation in M-mode echocardiography. Results of a survey of echocardiographic measurements
22. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography
23. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings
24. Improvements in echocardiographic LV mass measurement yield and non-randomness of missing measurements: Strong Heart and Framingham Studies
25. Impact of type II diabetes on left ventricular geometry and function: The Hypertension Genetic Epidemiology Network (HyperGEN) Study
26. The association of carotid atherosclerosis and left ventricular hypertrophy
27. Reliability of echocardiographic assessment of left ventricular structure and function
28. Left ventricular mass and body size in normotensive children and adults: Assessment of allometric relations and of the impact of overweight
29. Effect of growth on variability of left ventricular mass: Assessment of allometric signals in adults and children and of their capacity to predict cardiovascular risk
30. Amplifier function of resistance vessels and the left ventricle in hypertension
31. Factors influencing the success of withdrawal of antihypertensive drug therapy
32. Relation of hemodynamic load to left ventricular hypertrophy and performance in hypertension
33. Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: The LIFE Study
34. Relation of left ventricular hemodynamic load and contractile performance to left ventricular mass in hypertension
35. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular hypertrophy in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study
36. Effects of once-daily angiotensin converting enzyme inhibition and calcium channel blockade on left ventricular hypertrophy and diastolic filling in hypertension: The PRESERVE Trial
37. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension
38. Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension
39. Alpha-blockade and thiazide treatment of hypertension. A double-blind randomized trial comparing doxazosin and hydrochlorothiazide